Global Medical REIT Announces $0.75 Dividend Payment

Written by Emily J. Thompson, Senior Investment Analyst

GMRE+0.91%

Source: SeekingAlpha

Updated: Dec 04 2025

0mins

Source: SeekingAlpha

Quarterly Dividend Announcement: Global Medical REIT (GMRE) has declared a quarterly dividend of $0.75 per share, with a forward yield of 9.19%.
Dividend Payment Details: The dividend is payable on January 9, for shareholders of record on December 19, with an ex-dividend date also set for December 19.
Preferred Stock Offering: GMRE has priced a new preferred stock offering at $50 million, with shares priced at $25.00 each.
Market Activity: AEW Capital has exited six REITs in Q3 and initiated a position in American Tower, indicating shifts in investment strategies within the REIT sector.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like GMRE with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

GMRE

$34.24+Infinity%1D

Analyst Views on GMRE

Wall Street analysts forecast GMRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMRE is 37.83 USD with a low forecast of 35.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 33.930

Low

35.00

Averages

37.83

High

41.00

Current: 33.930

Low

35.00

Averages

37.83

High

41.00

Baird

Neutral

downgrade

$45 -> $41

2025-11-11

Reason

Baird

Price Target

$45 -> $41

AI Analysis

2025-11-11

downgrade

Neutral

Reason

Baird lowered the firm's price target on Global Medical REIT to $41 from $45 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results which suggest the tough capital markets may lead to asset recycling.

Alliance Global Partners

Gaurav Mehta

Buy

downgrade

2025-05-29

Reason

Alliance Global Partners

Gaurav Mehta

Price Target

2025-05-29

downgrade

Buy

Reason

Alliance Global Partners analyst Gaurav Mehta lowered the firm's price target on Global Medical REIT to $8.50 from $9.50 and keeps a Buy rating on the shares. The company lowered its common dividend by 28.6%, which is the "right step" given the prior dividend was not covered by 2025 and 2026 estimates, the analyst tells investors in a research note. Going forward, the firm believes improved portfolio performance, including an improvement in occupancy, resolving of tenant issues such as Prospect Medical and the closure of the CEO search could be a positive catalyst for the stock.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GMRE

Unlock Now

About GMRE

Global Medical REIT Inc. is an internally managed real estate investment trust (REIT). The Company acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. The Company conducts its business through a wholly owned subsidiary of its operating partnership, Global Medical REIT L.P. It owns 92.6% of the outstanding common operating partnership units (OP Units) of its operating partnership, with an aggregate of 7.4% of the Operating Partnership owned by holders of long-term incentive plan units (LTIP Units) and third-party limited partners who contributed properties or services to the operating partnership in exchange for OP Units. Its portfolio includes medical office buildings (MOBs), inpatient rehab. facility (IRF), surgical hospitals and others. The Company's portfolio is located in various areas, including Texas, Florida, Ohio, Pennsylvania, Illinois, Arizona, and Michigan.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.